Generic Name and Formulations:
Hepatitis A vaccine, inactivated 25Units per 0.5mL (pediatric/adolescent), or 50Units per 1mL (adult); susp for IM inj; aluminum adsorbed; preservative-free.
Merck & Co., Inc.
Indications for VAQTA:
Hepatitis A immunization.
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later.
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later.
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature.
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects.
Prefilled syringes (0.5mL, 1mL)—1, 5; Single-dose vials (0.5mL)—1, 10; Single-dose vials (1mL)—1, 5, 10
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds